{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-22-069168","form_type":"8-K","ticker":"OCUL","cik":"0001393434","company_name":"OCULAR THERAPEUTIX, INC","filed_at":"2022-06-08T23:59:59+00:00","discovered_at":"2026-05-14T18:04:00.454143+00:00","generated_at":"2026-06-25T03:28:21.053514+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"President/CMO Michael Goldstein to depart June 30; Rabia Ozden named new CMO","bullets":["Michael Goldstein, President Ophthalmology and CMO, leaves OCUL on June 30, 2022.","Rabia Gurses Ozden, SVP Clinical Development, becomes Chief Medical Officer on July 1, 2022.","Goldstein enters consulting agreement from July 2022 to June 2023, renewable to 2026, at $6,000/month.","Consulting agreement includes non-competition and non-solicitation provisions."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-22-069168","json":"https://secwatch.observer/filing/0001104659-22-069168.json","markdown":"https://secwatch.observer/filing/0001104659-22-069168.md","text":"https://secwatch.observer/filing/0001104659-22-069168.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1393434/000110465922069168/0001104659-22-069168-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1393434/000110465922069168/tm2217977d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-25T03:28:21.053514+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"5a9c4da09d","claim":"Michael Goldstein departed as President, Ophthalmology and Chief Medical Officer at OCULAR THERAPEUTIX, INC.","evidence_excerpt":"On June 3, 2022, Michael Goldstein, M.D., President, Ophthalmology and Chief Medical Officer of Ocular Therapeutix, Inc. (the “Company”) and the Company mutually agreed that Dr. Goldstein would depart the Company to pursue other business opportunities, effective June 30, 2022 (the “Separation Date”).","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1393434/000110465922069168/0001104659-22-069168-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"departed"},{"label":"Role","value":"President, Ophthalmology and Chief Medical Officer"}],"fact_type":"executive_change"},{"claim_id":"69618403a8","claim":"Rabia Gurses Ozden was appointed as Chief Medical Officer at OCULAR THERAPEUTIX, INC.","evidence_excerpt":"In connection with his departure, Rabia Gurses Ozden, M.D., Senior Vice President, Clinical Development of the Company, has agreed to assume the role of Chief Medical Officer of the Company, effective on July 1, 2022.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1393434/000110465922069168/0001104659-22-069168-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Medical Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}